Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estradiol Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ATM | Q13315 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.77 |
| ▸ | SHBG | P04278 | 2/20 | 0.77 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.77 |
| ▸ | HTR2B | P41595 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estradiol Acetate SCHEMBL2099105 | 1.00 | ESR1 (1.00) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| Estradiol Acetate SCHEMBL20874461 | 1.00 | ESR1 (1.00) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| Estradiol Acetate SCHEMBL148561 | 1.00 | ESR1 (1.00) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| Estradiol Acetate SCHEMBL13712636 | 1.00 | ESR1 (1.00) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| Estradiol Acetate SCHEMBL29575955 | 1.00 | ESR1 (1.00) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| SCHEMBL28792824 | 0.94 | ESR1 (0.88) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| SCHEMBL28792822 | 0.93 | LMNA (0.86) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| SCHEMBL14598795 | 0.92 | LMNA (0.85) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| SCHEMBL14257109 | 0.91 | LMNA (0.83) | ESR1LMNASMN1; SMN2ADORA3ATM | |
| SCHEMBL9273489 | 0.91 | LMNA (0.83) | ESR1LMNASMN1; SMN2ADORA3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-20100092536-A1 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100092536-A1 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20090203632-A1 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090203632-A1 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090192214-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192214-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20080312315-A1 | Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use | ANGIOTECH PHARMACEUTICALS(US),INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312315-A1 | Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use | ANGIOTECH PHARMACEUTICALS(US),INC. (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203632-A1 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE | COL2A1, FN1, TNNC1 | ESR1 4702/4885LMNA 1072/4885SMN1; SMN2 175/4885 |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | MMP1, COL2A1, FN1 | ESR1 2297/4885LMNA 1905/4885SMN1; SMN2 3201/4885 |
| US-20100092536-A1 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | MMP1, CDKN1A, MKI67 | ESR1 1338/4885LMNA 3440/4885SMN1; SMN2 4422/4885 |
| US-20090192214-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | PGF, VCAM1, COL14A1 | ESR1 3562/4885LMNA 1945/4885SMN1; SMN2 2322/4885 |
| US-20080312315-A1 | Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use | ILK, PLOD3, MMP1 | ESR1 1908/4885LMNA 1008/4885SMN1; SMN2 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.